Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2014 from OUS - Department of Gynaecological Oncology

24 publications found

Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B (2014)
Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma
Int J Gynecol Cancer, 24 (9 Suppl 3), S67-72
DOI 10.1097/IGC.0000000000000205, PubMed 25033257

Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP (2014)
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Hum Pathol, 46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994

Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE (2014)
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
Virchows Arch, 464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216

Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK (2014)
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
Hum Pathol, 45 (7), 1520-8
DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803

Davidson B, Tropé CG (2014)
Ovarian cancer: diagnostic, biological and prognostic aspects
Womens Health (Lond), 10 (5), 519-33
DOI 10.2217/whe.14.37, PubMed 25335543

Davidson B, Tropé CG, Reich R (2014)
The clinical and diagnostic role of microRNAs in ovarian carcinoma
Gynecol Oncol, 133 (3), 640-6
DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546

Davidson B, Trope CG, Reich R (2014)
The role of the tumor stroma in ovarian cancer
Front Oncol, 4, 104
DOI 10.3389/fonc.2014.00104, PubMed 24860785

Friedlander ML, Covens A, Glasspool RM, Hilpert F, Kristensen G, Kwon S, Selle F, Small W, Witteveen E, Russell P (2014)
Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract
Int J Gynecol Cancer, 24 (9 Suppl 3), S78-82
DOI 10.1097/IGC.0000000000000239, PubMed 25341585

Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK (2014)
Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
Radiother Oncol, 113 (1), 132-8
DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501

Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2014)
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
PLoS One, 9 (11), e112209
DOI 10.1371/journal.pone.0112209, PubMed 25380303

Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B (2014)
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
BMC Cancer, 14, 68
DOI 10.1186/1471-2407-14-68, PubMed 24498853

Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S (2014)
Genomic profile of ovarian carcinomas
BMC Cancer, 14, 315
DOI 10.1186/1471-2407-14-315, PubMed 24886194

Micci F, Panagopoulos I, Thorsen J, Davidson B, Tropé CG, Heim S (2014)
Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
PLoS Biol, 12 (2), e1001784
DOI 10.1371/journal.pbio.1001784, PubMed 24504521

Nielsen B, Hveem TS, Kildal W, Abeler VM, Kristensen GB, Albregtsen F, Danielsen HE (2014)
Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas
Cytometry A, 87 (4), 315-25
DOI 10.1002/cyto.a.22601, PubMed 25483227

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014)
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
J Clin Oncol, 32 (13), 1302-8
DOI 10.1200/JCO.2013.51.4489, PubMed 24637997

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W (2014)
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma
Int J Gynecol Cancer, 24 (9 Suppl 3), S83-9
DOI 10.1097/IGC.0000000000000264, PubMed 25341586

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290

Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
Genes Chromosomes Cancer, 53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323

Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD (2014)
Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010)
Eur J Cancer, 50 (11), 1942-50
DOI 10.1016/j.ejca.2014.03.288, PubMed 24857045

Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD (2014)
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
Gynecol Oncol, 136 (2), 224-9
DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159

Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B (2014)
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
Am J Clin Pathol, 142 (1), 51-7
DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085

Vaksman O, Tropé C, Davidson B, Reich R (2014)
Exosome-derived miRNAs and ovarian carcinoma progression
Carcinogenesis, 35 (9), 2113-20
DOI 10.1093/carcin/bgu130, PubMed 24925027

Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B (2014)
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
BMC Cancer, 14, 80
DOI 10.1186/1471-2407-14-80, PubMed 24512620

Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G (2014)
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
BMC Cancer, 14, 937
DOI 10.1186/1471-2407-14-937, PubMed 25494701

 
Page visits: 71042